Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Table 1 demonstrates Aldeyra Therapeutics Inc. and Neuralstem Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Risk and Volatility

Aldeyra Therapeutics Inc.s 0.5 beta indicates that its volatility is 50.00% less volatile than that of S&P 500. Neuralstem Inc.s 94.00% more volatile than S&P 500 which is a result of the 1.94 beta.

Liquidity

The Current Ratio and a Quick Ratio of Aldeyra Therapeutics Inc. are 9.2 and 9.2. Competitively, Neuralstem Inc. has 3.8 and 3.8 for Current and Quick Ratio. Aldeyra Therapeutics Inc.s better ability to pay short and long-term obligations than Neuralstem Inc.

Institutional and Insider Ownership

Institutional investors held 69.9% of Aldeyra Therapeutics Inc. shares and 4.9% of Neuralstem Inc. shares. Aldeyra Therapeutics Inc.s share held by insiders are 2.2%. Insiders Competitively, held 1% of Neuralstem Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aldeyra Therapeutics Inc. was less bearish than Neuralstem Inc.

Summary

On 9 of the 9 factors Aldeyra Therapeutics Inc. beats Neuralstem Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Reviewing Aldeyra Therapeutics Inc. (ALDX)'s and Neuralstem Inc. (NASDAQ:CUR)'s results - MS Wkly